Adalimumab biosimilar CYLTEZO receives FDA approval
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 28, 2017 Category: Research Source Type: news

FDA Approves Second Humira Biosimilar, Cyltezo FDA Approves Second Humira Biosimilar, Cyltezo
Adalimumab-adbm Cyltezo, from Boehringer Ingelheim, is approved for multiple indications including treatment of adults with moderate-to-severe active rheumatoid arthritis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Second Humira Biosimilar Approved
(MedPage Today) -- FDA announces approval of Cyltezo (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 25, 2017 Category: American Health Source Type: news

Samsung, Biogen version of AbbVie's Humira approved in Europe
(Reuters) - Biogen Inc's version of AbbVie Inc's blockbuster arthritis drug Humira has been approved by European Union regulators, Biogen and joint venture partner Samsung Biologics said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - August 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Finger prick test allows patients taking autoimmune drug to avoid blood draws
(Wiley) A new study shows that patients with rheumatoid arthritis and other autoimmune conditions who take the drug adalimumab can monitor drug levels in their bodies with a finger prick rather than undergoing a full blood draw. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2017 Category: International Medicine & Public Health Source Type: news

Boehringer Ingelheim initiates interchangeability trial of BI 695501 and Humira
Boehringer Ingelheim has initiated patient enrolment in an interchangeability clinical trial (VOLTAIRE-X) of its product candidate BI 695501 and the US-marketed formulation of 40mg/0.8mL Humira. (Source: Drug Development Technology)
Source: Drug Development Technology - July 30, 2017 Category: Pharmaceuticals Source Type: news

AbbVie to remain cautious on drug pricing, shares fall
(Reuters) - AbbVie Inc's said it would be cautious with drug pricing, especially for Humira, the world's biggest selling drug, sending its shares down 2 percent, despite the drugmaker's quarterly profit narrowly beating estimates. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie's profit beats on Humira, Imbruvica demand
(Reuters) - U.S. drugmaker AbbVie Inc reported quarterly earnings on Friday that edged past analysts' expectations, helped by robust demand for its flagship rheumatoid arthritis drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie's profit beats on robust Humira demand
(Reuters) - U.S. drugmaker AbbVie Inc reported quarterly earnings on Friday that edged past analysts' expectations, helped by robust demand for its flagship rheumatoid arthritis drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie's profit rises 19 percent on Humira demand
(Reuters) - U.S. drugmaker AbbVie Inc reported an 18.9 percent rise in quarterly profit on Friday on strong demand for its flagship rheumatoid arthritis drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Interchangeability study on BI 695501 vs Humira
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 26, 2017 Category: Research Source Type: news

CHMP Recommends Imraldi, a Biosimilar to Humira CHMP Recommends Imraldi, a Biosimilar to Humira
The CHMP has recommended Imraldi, a biosimilar to Humira.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 24, 2017 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

EU backs second biosimilar copy of Humira, world's top drug
FRANKFURT (Reuters) - European regulators have recommended approval of a second copy of AbbVie's rheumatoid arthritis drug Humira, the world's top-selling medicine, in a further boost for so-called biosimilars in the region. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Pregnancy and the Pharmacokinetics of Anti-TNF Agents in IBD Pregnancy and the Pharmacokinetics of Anti-TNF Agents in IBD
This study found that infliximab and adalimumab present differing effects.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New Biosimilar for Adalimumab in Rheumatoid Arthritis New Biosimilar for Adalimumab in Rheumatoid Arthritis
A large multinational study compares the efficacy and safety of FKB327 biosimilar to adalimumab in active rheumatoid arthritis. But antidrug antibody levels raise questions.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news